Latest Financials News

Moho Resources has completed the sale of its Empress Springs Project, securing an initial payment of $408,500 with a deferred $300,000 to follow next year, reinforcing its asset optimisation strategy.

Hutchison Telecommunications (Amsterdam) B.V. has announced an off-market takeover bid for the 12.13% of Hutchison Telecommunications (Australia) Limited shares it does not already own, offering a 52.4% premium. The move aims to consolidate full ownership of the Australian telecom operator.

Comms Group Ltd launches a $7 million capital raising, including a fully underwritten entitlement offer, to acquire Tasmanian IT services provider TasmaNet, aiming to boost its revenue and market reach significantly.

GQG Partners reported robust financial results for 2024 with significant growth in funds under management and earnings, underscoring its adaptability and alignment with shareholders. The 2025 Annual Meeting confirmed strong investor confidence with near-unanimous director re-election.

Solstice Minerals has pinpointed promising mineral resource extension targets at its Nanadie Copper-Gold Project in Western Australia, setting the stage for a potential significant increase in copper and gold resources.

Australian Agricultural Company Limited (AACo) reported a 14% rise in operating profit to $58.4 million for FY25, driven by increased sales volumes and disciplined cost control despite challenging market conditions. The company also marked a significant reduction in statutory loss, signaling improved financial resilience.

Australian Agricultural Company Limited (AACo) reported a robust FY25 operating profit of $58.4 million, driven by increased meat and cattle sales volumes and strategic brand growth despite inflationary pressures.

Australian Agricultural Company Limited (AACo) has reported a robust turnaround in its FY25 results, with significant gains in revenue and profitability driven by higher sales volumes and improved operational efficiency.

Oceania Healthcare reported a 4.1% rise in underlying EBITDA for FY25, driven by strong sales and operational improvements, while launching a new strategic plan focused on growth and efficiency.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

AFT Pharmaceuticals reported a 6% increase in revenue to NZ$208 million for the year ending March 2025, but net profit fell 23%, prompting a modest final dividend declaration.